Non-coding DNA variants contribute to acute lymphoblastic leukemia (ALL) chemotherapy resistance. St. Jude Children's Research Hospital scientists have identified specific DNA variants in the ...

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's ...

The healthcare industry is no stranger to technological advancements, and artificial intelligence (AI) is quickly becoming a game-changer in multiple areas. From diagnosing medical conditions to ...

Just as species adapt over generations, our body's cells accumulate DNA changes throughout life. Most are harmless, yet a few "driver" mutations give a cell a competitive edge and can spark cancer.

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial.